SK Life Science
NJ - ParamusBiotechnology
Focus: SK Life Science is a public specialty pharma company focused on small-molecule treatments for CNS disorders, anchored by XCOPRI (cenobamate) for epilepsy. The company operates as a U.S. hub for SK Biopharmaceuticals' global innovation strategy.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
14-1 this month
Stable — net -1 jobs in 30d
7 added, 8 removed. Backfill posture.
Should You Work at SK Life Science?
AI assessmentSK Life Science is a narrow-focus specialty play suitable for Medical Affairs or Commercial professionals seeking stability in a single-product franchise, but risky for those expecting pipeline-driven growth or R&D investment.
Why Work Here
- XCOPRI at peak sales ($113M Part D spending) with LOE protection until 2039 provides revenue stability for a lean organization
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
14 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$113M Part DStable
Peak12.8yr
Sole revenue driver; sodium channel antagonist with 13-year patent runway provides predictable cash flow.
Help build intelligence for SK Life Science
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.